SEC Form 4 · accession 0001209191-16-136532
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Blight
Officer — Chief Scientific Officer
Period of report
Aug 9, 2016
Accepted (ET)
Aug 11, 2016 · 3:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 9, 2016 | M | 9,754 | $22.13 | A | 81,413 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $22.13 | Aug 9, 2016 | M | 9,754 | D | — | Feb 14, 2017 | Common Stock | 9,754 | 67,586 | D |
Explanation of responses
- F1The shares subject to these options vested in installments and were fully vested on January 1, 2011.